From: Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia
lncRNAs | Altered expression | Targets | Function | Reference |
---|---|---|---|---|
PVT1 | ↑in AEL/APL |  | Protect MYC from degradation to promoted promyelocytes proliferation | [163] |
CRNDE | ↑in AML cell lines |  | Promote cell proliferation and arrest cell cycle in G0-G1 phase | [168] |
MEG3 | ↓in AML |  | Promote AML leukemogenesis | [172] |
CCD26 | ↑in NPM1-mutated AML | c-Kit | Control the growth of AML cells | [176] |
H19 | ↑in AML-M2 patients | has-miR-19a/b | Regulated the expression of ID2 through competitive binding to miR-19a/b to increase cells proliferation | [186] |
NEAT1 | ↓in AML blood sample and AML cell lines | miR-23a-3p | Increase myeloid cell proliferation and ATRA-induced myeloid differentiation, and induce apoptosis | [187] |
UCA1 | ↑in AML cell lines and CN-AMLwith biallelic CEBPA | miR-126, RAC1 | Increased cell proliferation, inhibited apoptosis, migration, and invasion by sponging miR-126 | [188] |
↑in AML cell lines and CN-AML with biallelic CEBPA | p27kip1 | Role in promoting cells proliferation is to sequester hnRNP I to inhibit the expression of the cell cycle regulator p27kip1 | [167] | |
↑in HL-60 and HL-60/ADR | miR-125a | Poor chemotherapy overcome | [189] | |
HOTAIR | ↑in de novo AML patients | miR-193a;c-Kit | Increase AML cells proliferation, inhibited apoptosis and infiltration of leukemic blasts and number of AML cells colony formation, and shorten overall survival time | [190] |
↑in LSC | p15 | Promote the self-renewal of leukemia stem cells | [191] | |
CCAT1 | ↑in HL60 and AML PB | miR-155, c-Myc | Upregulated c-Myc expression to increased cells proliferation and differentiation by its competing endogenous RNA (ceRNA) activity on miR-155 | [192] |
FTX | ↑in U937 and THP-1 | miR-342, ALG3 | Drug resistance | [193] |
PANDAR | ↑ANDARLINK |  | Predict adverse prognosis in AML | [181] |
HOXA-AS2 | ↑in APL | TRAIL-mediated pathway | Lead to fine-tuning of apoptosis during ATRA-induced myeloid differentiation | [194] |
↑00PERLINK \l "_ENREF_200" \o "Zhao H, 2013 #197" or><adriamycin-based chemotherapy and in U/A and T/A cells | miR-520c-3p/S100A4 Axis | Knockdown of lncRNA HOXA-AS2 inhibited ADR cell proliferation and chemoresistance of AML by the miR-520c-3p/S100A4 Axis, and promoted apoptosis | [195] | |
HOTAIRM1 | ↑in AML cell lines | HOXA1, HOXA4, CD11b,CD18,miR-20a/106b miR-125b | Regulate myeloid cell differentiation and cell cycle via enhancing the autophagy pathway and PML-RARα degradation | [161] |
IRAN | ↑in AML | IGF1R | long-range DNA interactions | [199] |
RUNXOR | ↑in AML | RUNX1 | Participate in chromosomal translocation | [200] |
ANRIL | ↑in AML patients at diagnosis ↓in patients after CR | ANRIL/AdipoR1/AMPK/SIR pathway | Promote cell survival | [201] |
vtRNA2-1 | Â | Â | Regulate pPKR | [202] |
linc-223 | ↓in AML cell lines | IRF4; miR-125-5p | Control proliferation and differentiation of AML cells and IRF4 downregulation by binding miR-125-5p | [203] |
LINC00899 | ↑INC00899K \l "_ENREF_13patients |  | As a novel serum biomarker for diagnosis and prognosis of AML | [204] |